Brief Description
Iaterion is a biopharma company developing novel therapeutics for women's health and diseases. The company develops targeted selective nuclear receptor drugs addressing multiple indications encountered by women and focuses on novel drugs as an alternative to menopausal hormone therapy (MHT). The company was founded to commercialize a novel discovery made by UC Berkeley Adjunct Professor in the Department of Nutritional Sciences Dale Leitman, MD, PhD, for nuclear receptors reprogramming (NRRP) agents.
Iaterion's team brings decades of experience in the bio-pharmaceutical industry. The team has engaged in all levels of scientific and industrial small molecules and biologics development.
Iaterion's drugs are harnessing its platform for selective nuclear receptor modulators, including NRRPs, receptor subtype selective drugs and tissue specific selective drugs.
Timeline
- 2014. Company founded.
Inventor
Dale Leitman